Cerus Corporation (CERS)

Market Cap	300.93M
Revenue (ttm)	186.80M
Net Income (ttm)	-37.49M
Shares Out	181.28M
EPS (ttm)	-0.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	579,742
Open	1.680
Previous Close	1.680
Day's Range	1.650 - 1.705
52-Week Range	1.210 - 3.080
Beta	1.30
Analysts	Buy
Price Target	2.75 (+65.66%)
Earnings Date	May 2, 2024

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 625
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS

Financial Performance

In 2023, Cerus's revenue was $186.80 million, a decrease of -0.81% compared to the previous year's $188.32 million. Losses were -$37.49 million, -12.37% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $2.75, which is an increase of 65.66% from the latest price.

Price Target

$2.75

(65.66% upside)

Analyst Consensus: Buy